Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Animal Diseases HELP
Based on 100,000 articles published since 2009
|||| 27 

These are the 100000 published articles about Animal Diseases that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline International Society for Companion Animal Infectious Diseases (ISCAID) guidelines for the diagnosis and management of bacterial urinary tract infections in dogs and cats. 2019

Weese, J Scott / Blondeau, Joseph / Boothe, Dawn / Guardabassi, Luca G / Gumley, Nigel / Papich, Mark / Jessen, Lisbeth Rem / Lappin, Michael / Rankin, Shelley / Westropp, Jodi L / Sykes, Jane. ·Dept of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, N1G2W1, Canada. Electronic address: jsweese@uoguelph.ca. · Clinical Microbiology, Royal University Hospital and the Saskatchewan Health Authority, Saskatoon, SK, Canada; Departments of Microbiology and Immunology, Pathology and Laboratory Medicine and Ophthalmology, University of Saskatchewan, Saskatoon, SK, Canada. · Department of Anatomy, Physiology and Pharmacology, Auburn University, 36849, USA. · Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Stigbøjlen 4, 1870 Frederiksberg C, Denmark; Department of Pathobiology and Population Sciences, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, Herts, AL9 7TA, United Kingdom. · Cedarview Animal Hospital, 4100 Strandherd Dr, #106, Ottawa, ON K2J 0V2, Canada. · Department of Molecular Biomedical Sciences, North Carolina State University, College of Veterinary Medicine,4700 Hillsborough Street, Raleigh, NC 27606, USA. · Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Dyrlaegevej 16, 1870 Frederiksberg C, Denmark. · Department of Clinical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO 80523, USA. · School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St, Philadelphia, PA 19104, USA. · School of Veterinary Medicine, Department of Medicine & Epidemiology, 2108 Tupper Hall, University of California-Davis, Davis, CA 95616, USA. ·Vet J · Pubmed #30971357.

ABSTRACT: Urinary tract disease is a common clinical presentation in dogs and cats, and a common reason for antimicrobial prescription. This document is a revision and expansion on the 2011 Antimicrobial Use Guidelines for Treatment of Urinary Tract Disease in Dogs and Cats, providing recommendations for diagnosis and management of sporadic bacterial cystitis, recurrent bacterial cystitis, pyelonephritis, bacterial prostatitis, and subclinical bacteriuria. Issues pertaining to urinary catheters, medical dissolution of uroliths and prophylaxis for urological procedures are also addressed.

2 Guideline 2019 AAHA Dental Care Guidelines for Dogs and Cats. 2019

Bellows, Jan / Berg, Mary L / Dennis, Sonnya / Harvey, Ralph / Lobprise, Heidi B / Snyder, Christopher J / Stone, Amy E S / Van de Wetering, Andrea G. ·From All Pets Dental, Weston, Florida (J.B.) · Beyond the Crown Veterinary Education, Lawrence, Kansas (M.L.B.) · Stratham-Newfields Veterinary Hospital, Newfields, New Hampshire (S.D.) · Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee (R.H.) · Main Street Veterinary Dental Hospital, Flower Mount, Texas (H.B.L.) · Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin (C.J.S.) · Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, Florida (A.E.S.S.) · and Advanced Pet Dentistry, LLC, Corvallis, Oregon (A.G.VdW.). ·J Am Anim Hosp Assoc · Pubmed #30776257.

ABSTRACT: The 2019 AAHA Dental Care Guidelines for Dogs and Cats outline a comprehensive approach to support companion animal practices in improving the oral health and often, the quality of life of their canine and feline patients. The guidelines are an update of the 2013 AAHA Dental Care Guidelines for Dogs and Cats. A photographically illustrated, 12-step protocol describes the essential steps in an oral health assessment, dental cleaning, and periodontal therapy. Recommendations are given for general anesthesia, pain management, facilities, and equipment necessary for safe and effective delivery of care. To promote the wellbeing of dogs and cats through decreasing the adverse effects and pain of periodontal disease, these guidelines emphasize the critical role of client education and effective, preventive oral healthcare.

3 Guideline Clinical application of the American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines to small animal cases. 2019

Sharp, Claire R / Goggs, Robert / Blais, Marie-Claude / Brainard, Benjamin M / Chan, Daniel L / deLaforcade, Armelle M / Rozanski, Elizabeth. ·School of Veterinary and Life Sciences, College of Veterinary Medicine, Murdoch University, Murdoch, Australia. · Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY. · Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Quebec, Canada. · Department of Small Animal Medicine and Surgery, University of Georgia, Athens, GA. · Department Clinical Science and Services, The Royal Veterinary College, North Mymms, UK. · Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30729652.

ABSTRACT: OBJECTIVE: To illustrate the application of the Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines to the management of dogs and cats at risk of developing thrombosis using a case-based approach. ETIOLOGY: Dogs and cats become at risk of developing thrombosis from a wide range of conditions. These conditions often involve a specific insult followed by an inflammatory response and when combined with other contributing factors (eg, hypercoagulability, vascular endothelial injury, hemodynamic changes) create favorable conditions for thrombosis. DIAGNOSIS: Development of thrombosis in small animals remains challenging to demonstrate. Compatible clinical signs, the presence of known risk factors, and supporting diagnostic tests may be highly suggestive of the development of thrombosis. THERAPY: Therapeutic recommendations in accordance with the CURATIVE guidelines for dogs and cats are described in specific case vignettes presented. Discussion is centered on antithrombotic drug choices and dosing protocols, as outlined in Domains 2 and 3 of the CURATIVE guidelines. Where appropriate, guidelines related to therapeutic monitoring (Domain 4) and discontinuation of antithrombotics (Domain 5) were included. PROGNOSIS: In small animals at risk of developing thrombosis, overall prognosis may be improved by following consensus-based recommendations on the use of antithrombotics as outlined in the CURATIVE guidelines. Whether such interventions have any impact on outcome requires further investigation.

4 Guideline Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 5-Discontinuation of anticoagulant therapy in small animals. 2019

Brainard, Benjamin M / Buriko, Yekaterina / Good, Jennifer / Ralph, Alan G / Rozanski, Elizabeth A. ·Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA. · Department of Clinical Studies, Philadelphia, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA. · MedVet New Orleans, New Orleans, LA. · Department of Clinical Sciences, Tufts Cummings School of Veterinary Medicine, North Grafton, MA. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654425.

ABSTRACT: OBJECTIVES: To systematically evaluate the evidence supporting the timing and mechanisms of permanent or temporary discontinuation of antiplatelet or anticoagulant medications in small animals DESIGN: Standardized, systematic evaluation of the literature, categorization of relevant articles according to level of evidence and quality (poor, fair, or good), and development of consensus on conclusions via a Delphi-style survey for application of the concepts to clinical practice. SETTINGS: Academic and referral veterinary medical centers. RESULTS: Databases searched included Medline via PubMed and CAB abstracts. Two specific courses of inquiry were pursued, one focused on appropriate approaches to use for small animal patients receiving antiplatelet or anticoagulant drugs and requiring temporary discontinuation of this therapy for the purposes of invasive procedures (eg, surgery), and the other aimed at decision-making for the complete discontinuation of anticoagulant medications. In addition, the most appropriate methodology for discontinuation of heparins was addressed. CONCLUSIONS: To better define specific patient groups, a risk stratification characterization was developed. It is recommended to continue anticoagulant therapy through invasive procedures in patients at high risk for thrombosis that are receiving anticoagulant therapy, while consideration for discontinuation in patients with low to moderate risk of thrombosis is reasonable. In patients with thrombosis in whom the underlying cause for thrombosis has resolved, indefinite treatment with anticoagulant medication is not recommended. If the underlying cause is unknown or untreatable, anticoagulant medication should be continued indefinitely. Unfractionated heparin therapy should be slowly tapered rather than discontinued abruptly.

5 Guideline Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 1-Defining populations at risk. 2019

deLaforcade, Armelle / Bacek, Lenore / Blais, Marie-Claude / Goggs, Robert / Lynch, Alex / Rozanski, Elizabeth. ·Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA. · Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL. · Department of Clinical Sciences, University of Montreal, Saint-Hyacinthe, QC, Canada. · Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY. · Department of Clinical Sciences, NC State College of Veterinary Medicine, Raleigh, NC. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654424.

ABSTRACT: OBJECTIVES: Thrombosis is a well-recognized phenomenon in dogs and cats with a significant impact on morbidity and mortality. Despite growing awareness of thrombosis and increased use of antithrombotic therapy, there is little information in the veterinary literature to guide the use of anticoagulant and antiplatelet medications. The goal of Domain 1 was to explore the association between disease and thrombosis in a number of conditions identified as potential risk factors in the current veterinary literature, to provide the basis for prescribing recommendations. DESIGN: A population exposure comparison outcome format was used to represent patient, exposure, comparison, and outcome. Population Exposure Comparison Outcome questions were distributed to worksheet authors who performed comprehensive searches, summarized the evidence, and created guideline recommendations that were reviewed by domain chairs. Revised guidelines then underwent the Delphi survey process to reach consensus on the final guidelines. Diseases evaluated included immune-mediated hemolytic anemia, protein-losing nephropathy, pancreatitis, glucocorticoid therapy, hyperadrenocorticism, neoplasia, sepsis, cerebrovascular disease, and cardiac disease. SETTINGS: Academic and referral veterinary medical centers. RESULTS: Of the diseases evaluated, a high risk for thrombosis was defined as dogs with immune-mediated hemolytic anemia or protein-losing nephropathy, cats with cardiomyopathy and associated risk factors, or dogs/cats with >1 disease or risk factor for thrombosis. Low or moderate risk for thrombosis was defined as dogs or cats with a single risk factor or disease, or dogs or cats with known risk factor conditions that are likely to resolve in days to weeks following treatment. CONCLUSIONS: Documented disease associations with thrombosis provide the basis for recommendations on prescribing provided in subsequent domains. Numerous knowledge gaps were identified that represent opportunities for future study.

6 Guideline American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines: Small animal. 2019

Goggs, Robert / Blais, Marie-Claude / Brainard, Benjamin M / Chan, Daniel L / deLaforcade, Armelle M / Rozanski, Elizabeth / Sharp, Claire R. ·Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY. · Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada. · Department of Small Animal Medicine and Surgery, University of Georgia, Athens, GA. · Department Clinical Science and Services, The Royal Veterinary College, London, United Kingdom. · Department of Clinical Sciences, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA. · School of Veterinary and Life Sciences, College of Veterinary Medicine, Murdoch University, Murdoch, WA, Australia. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654421.

ABSTRACT: OBJECTIVES: To systematically review available evidence and establish guidelines related to the risk of developing thrombosis and the management of small animals with antithrombotics. DESIGN: Standardized, systematic evaluation of the literature (identified by searching Medline via PubMed and CAB abstracts) was carried out in 5 domains (Defining populations at risk; Defining rational therapeutic use; Defining evidence-based protocols; Refining and monitoring antithrombotic therapies; and Discontinuing antithrombotic therapies). Evidence evaluation was carried out using Population, Intervention, Comparison, Outcome generated within each domain questions to address specific aims. This was followed by categorization of relevant articles according to level of evidence and quality (Good, Fair, or Poor). Synthesis of these data led to the development of a series of statements. Consensus on the final guidelines was achieved via Delphi-style surveys. Draft recommendations were presented at 2 international veterinary conferences and made available for community assessment, review, and comment prior to final revisions and publication. SETTINGS: Academic and referral veterinary medical centers. RESULTS: Over 500 studies were reviewed in detail. Worksheets from all 5 domains generated 59 statements with 83 guideline recommendations that were refined during 3 rounds of Delphi surveys. A high degree of consensus was reached across all guideline recommendations. CONCLUSIONS: Overall, systematic evidence evaluations yielded more than 80 recommendations for the treatment of small animals with or at risk of developing thrombosis. Numerous significant knowledge gaps were highlighted by the evidence reviews undertaken, indicating the need for substantial additional research in this field.

7 Guideline Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 4-Refining and monitoring antithrombotic therapies. 2019

Sharp, Claire R / deLaforcade, Armelle M / Koenigshof, Amy M / Lynch, Alex M / Thomason, John M. ·School of Veterinary and Life Sciences, Murdoch University, Murdoch, WA, Australia. · Department of Clinical Sciences, Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA. · College of Veterinary Medicine, Michigan State University, East Lansing, MI. · Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC. · Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654420.

ABSTRACT: OBJECTIVES: To systematically review the evidence for therapeutic monitoring of antithrombotic drugs in small animals, develop guidelines regarding antithrombotic monitoring, and identify knowledge gaps in the field. DESIGN: First, a standardized, systematic literature review was conducted to address predefined PICO (Population/Patient, Intervention, Control, Outcome) questions, with categorization of relevant articles according to level of evidence and quality. Preliminary guidelines were developed by PICO worksheet authors and the domain chair. Thereafter, a Delphi-style survey was used to develop consensus on guidelines regarding therapeutic monitoring of antithrombotics in dogs and cats. SETTING: Academic and referral veterinary medical centers. RESULTS: PICO questions regarding the utility of therapeutic monitoring were developed for 6 different antithrombotic drugs or drug classes, including aspirin, clopidogrel, warfarin, unfractionated heparin, the low molecular weight heparins, and rivaroxaban, The majority of the literature pertaining to therapeutic monitoring of antithrombotic drugs was either performed in experimental animal models of disease or involved studies of drug pharmacokinetics and pharmacodynamics in healthy laboratory animals. There was a paucity of high level of evidence studies directly addressing the PICO questions, which limited the strength of recommendations that could be provided. The final guidelines recommend that therapeutic monitoring should be performed when using warfarin or unfractionated heparin in dogs and cats at risk of thrombosis. There is insufficient evidence to make strong recommendations for therapeutic monitoring of aspirin or low molecular weight heparin in dogs and cats at this time. CONCLUSIONS: As in other CURATIVE domains, significant knowledge gaps were highlighted, indicating the need for substantial additional research in this field. Ongoing investigation of the role of therapeutic monitoring of antithrombotic therapies will undoubtedly facilitate improved outcomes for dogs and cats at risk of thrombosis.

8 Guideline Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 3-Defining antithrombotic protocols. 2019

Blais, Marie-Claude / Bianco, Domenico / Goggs, Robert / Lynch, Alex M / Palmer, Lee / Ralph, Alan / Sharp, Claire R. ·Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, St-Hyacinthe, Quebec, Canada. · Internal Medicine Department, Metropolitan Animal Specialty Hospital, Los Angeles, CA. · Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY. · Department of Clinical Sciences, North Carolina State University, Raleigh, NC. · Lieutenant Colonel, US Army Reserve, Veterinary Corps, Chair K9 Tactical Emergency Casualty Care Working Group, New Orleans, LA. · MedVet New Orleans, New Orleans, LA. · School of Veterinary and Life Sciences, Murdoch University, Murdoch, Australia. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654416.

ABSTRACT: OBJECTIVES: To systematically examine the evidence for use of a specific protocol (dose, frequency, route) of selected antithrombotic drugs, in comparisons to no therapy or to other antithrombotic therapies, to reduce the risk of complications or improve outcomes in dogs and cats at risk for thrombosis. DESIGN: Standardized, systematic evaluation of the literature, categorization of relevant articles according to level of evidence (LOE) and quality (Good, Fair, or Poor), and development of consensus on conclusions via a Delphi-style survey for application of the concepts to clinical practice. SETTINGS: Academic and referral veterinary medical centers. RESULTS: Databases searched included Medline via PubMed and CAB abstracts. Eight different antithrombotic drugs were investigated using a standardized Patient, Intervention, Comparison, Outcome (PICO) question format both for dogs and cats, including aspirin, clopidogrel, warfarin, unfractionated heparin (UFH), dalteparin, enoxaparin, fondaparinux, and rivaroxaban, generating a total of 16 worksheets. Most studies identified were experimental controlled laboratory studies in companion animals (LOE 3) with only four randomized controlled clinical trials in companion animals (LOE 1). CONCLUSIONS: Overall, evidence-based recommendations concerning specific protocols could not be formulated for most antithrombotic drugs evaluated, either because of the wide range of dosage reported (eg, aspirin in dogs) or the lack of evidence in the current literature. However, clopidogrel administration in dogs and cats at risk of arterial thrombosis, notably in cats at risk of cardiogenic thromboembolism, is supported by the literature, and specific protocols were recommended. Comparably, aspirin should not be used as a sole antithrombotic in cats with cardiomyopathy. Using the available safety profile information contained in the literature, the panel reached consensus on suggested dosage schemes for most antithrombotics. Significant knowledge gaps were highlighted, which will hopefully drive novel research.

9 Guideline Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 2-Defining rational therapeutic usage. 2019

Goggs, Robert / Bacek, Lenore / Bianco, Domenico / Koenigshof, Amy / Li, Ronald H L. ·Department of Clinical Sciences, Cornell University College of Veterinary Medicine, Ithaca, NY. · Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL. · Metropolitan Animal Specialty Hospital, Los Angeles, CA. · Department of Small Animal Clinical Sciences, Michigan State University, East Lansing, MI. · Department of Veterinary Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA. ·J Vet Emerg Crit Care (San Antonio) · Pubmed #30654415.

ABSTRACT: OBJECTIVES: To systematically review available evidence to determine when small animals at risk of thrombosis should be treated with antiplatelet agents and anticoagulants, which antiplatelet and anticoagulant agents are most effective, and when multimodal therapy is indicated. DESIGN: Standardized, systematic evaluation of the literature, categorization of relevant articles according to level of evidence (LOE) and quality (Good, Fair, or Poor), and development of consensus on conclusions via a Delphi-style survey for application of the concepts to clinical practice. Draft recommendations were presented at 2 international veterinary conferences and made available for community assessment, review, and comment prior to final revisions and publication. SETTINGS: Academic and referral veterinary medical centers. RESULTS: Databases searched included Medline via PubMed and CAB abstracts. Twelve Population Intervention Comparison Outcome questions were devised and generated corresponding worksheets investigating indications for use of antithrombotic drugs in small animals. Seventy-eight studies were reviewed in detail. Most studies assessed were experimentally controlled laboratory studies in companion animals (56 LOE 3) with smaller numbers of LOE 2 (1), LOE 4 (5), LOE 5 (6), and LOE 6 (4) studies assessed. Only 5 randomized controlled clinical trials were identified (LOE 1, Good-Fair). The 12 worksheets generated 21 guidelines with 17 guideline statements that were refined during 3 rounds of Delphi surveys. A high degree of consensus was reached across all guideline recommendations during the Delphi process. CONCLUSIONS: Overall, systematic evidence evaluations generated 2 strong recommendations, 19 weak recommendations (formulated as suggestions), 9 situations where the evidence was insufficient to make strong recommendations, and 8 situations where no relevant evidence was retrieved to aid guideline generation. Numerous significant knowledge gaps were highlighted by the evidence reviews undertaken, indicating the need for substantial additional research in this field.

10 Guideline ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats. 2018

Marks, Stanley L / Kook, Peter H / Papich, Mark G / Tolbert, M K / Willard, Michael D. ·Department of Medicine & Epidemiology, School of Veterinary Medicine, University of California, Davis, Davis, California. · Vetsuisse Faculty, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. · Department of Molecular Biomedical Sciences, North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina. · Department of Small Animal Clinical Sciences, College of Veterinary Medicine, Texas A & M University, College Station, Texas. ·J Vet Intern Med · Pubmed #30378711.

ABSTRACT: The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of inflammatory, erosive, and ultimately ulcerative lesions. This report offers a consensus opinion on the rational administration of GI protectants to dogs and cats, with an emphasis on proton pump inhibitors (PPIs), histamine type-2 receptor antagonists (H

11 Guideline STANDARDS OF CARE Anaesthesia guidelines for dogs and cats. 2018

Warne, L N / Bauquier, S H / Pengelly, J / Neck, D / Swinney, G. ·Lecturer in Veterinary Anaesthesia, College of Veterinary Medicine, School of Veterinary and Life Sciences, Murdoch University, Murdoch, Western Australia, Australia. · Board of Directors - Regional Officer, American College of Veterinary Anesthesia and Analgesia; Senior Lecturer in Veterinary Anaesthesia, Melbourne Veterinary School, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, Victoria, Australia. · Vice President, Veterinary Nurses Council of Australia; Chair, National Industry Advisory Group for Veterinary Nurses; Training Consultant, Animal Industries Resource Centre; Veterinary Nurse, East Port Veterinary Hospital, Port Macquarie, New South Wales, Australia. · Deputy Board Member, Veterinary Surgeons' Board of Western Australia; Cottesloe Vet, Cottesloe, Western Australia, Australia. · Medical Affairs Veterinarian and Internal Medicine Consultant Australia and New Zealand, IDEXX Laboratories Pty Ltd, Rydalmere, New South Wales, Australia. ·Aust Vet J · Pubmed #30370594.

ABSTRACT: -- No abstract --

12 Guideline ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. 2018

Acierno, Mark J / Brown, Scott / Coleman, Amanda E / Jepson, Rosanne E / Papich, Mark / Stepien, Rebecca L / Syme, Harriet M. ·Department of Medicine, College of Veterinary Medicine, Midwestern University, 5715 W. Utopia Rd, Glendale Arizona 85308. · College of Veterinary Medicine, University of Georgia, Athens, Georgia. · Department of Clinical Science and Services, Royal Veterinary College, London, United Kingdom. · College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina. · Department of Medical Sciences, University of Wisconsin School of Veterinary Medicine, Madison, Wisconsin. ·J Vet Intern Med · Pubmed #30353952.

ABSTRACT: An update to the 2007 American College of Veterinary Internal Medicine (ACVIM) consensus statement on the identification, evaluation, and management of systemic hypertension in dogs and cats was presented at the 2017 ACVIM Forum in National Harbor, MD. The updated consensus statement is presented here. The consensus statement aims to provide guidance on appropriate diagnosis and treatment of hypertension in dogs and cats.

13 Guideline Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. 2018

Bøtker, Hans Erik / Hausenloy, Derek / Andreadou, Ioanna / Antonucci, Salvatore / Boengler, Kerstin / Davidson, Sean M / Deshwal, Soni / Devaux, Yvan / Di Lisa, Fabio / Di Sante, Moises / Efentakis, Panagiotis / Femminò, Saveria / García-Dorado, David / Giricz, Zoltán / Ibanez, Borja / Iliodromitis, Efstathios / Kaludercic, Nina / Kleinbongard, Petra / Neuhäuser, Markus / Ovize, Michel / Pagliaro, Pasquale / Rahbek-Schmidt, Michael / Ruiz-Meana, Marisol / Schlüter, Klaus-Dieter / Schulz, Rainer / Skyschally, Andreas / Wilder, Catherine / Yellon, Derek M / Ferdinandy, Peter / Heusch, Gerd. ·Department of Cardiology, Aarhus University Hospital, Palle-Juul Jensens Boulevard 99, 8200, Aarhus N, Denmark. haboet@rm.dk. · The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London, WC1E 6HX, UK. · The National Institute of Health Research, University College London Hospitals Biomedial Research Centre, Research and Development, London, UK. · National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore. · Yon Loo Lin School of Medicine, National University Singapore, Singapore, Singapore. · Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, 8 College Road, Singapore, 169857, Singapore. · Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. · Department of Biomedical Sciences, CNR Institute of Neuroscience, University of Padova, Via Ugo Bassi 58/B, 35121, Padua, Italy. · Institute for Physiology, Justus-Liebig University Giessen, Giessen, Germany. · Cardiovascular Research Unit, Luxembourg Institute of Health, Strassen, Luxembourg. · Department of Clinical and Biological Sciences, University of Torino, Turin, Italy. · Experimental Cardiology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. · Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary. · Pharmahungary Group, Szeged, Hungary. · Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), IIS-Fundación Jiménez Díaz, CIBERCV, Madrid, Spain. · Second Department of Cardiology, Faculty of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. · Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany. · Department of Mathematics and Technology, Koblenz University of Applied Science, Remagen, Germany. · Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen, Essen, Germany. · Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Lyon, France. · UMR, 1060 (CarMeN), Université Claude Bernard, Lyon1, Villeurbanne, France. · Department of Cardiology, Aarhus University Hospital, Palle-Juul Jensens Boulevard 99, 8200, Aarhus N, Denmark. · Institute for Pathophysiology, West German Heart and Vascular Center, University of Essen Medical School, Essen, Germany. gerd.heusch@uk-essen.de. ·Basic Res Cardiol · Pubmed #30120595.

ABSTRACT: -- No abstract --

14 Guideline Optimising experimental research in respiratory diseases: an ERS statement. 2018

Bonniaud, Philippe / Fabre, Aurélie / Frossard, Nelly / Guignabert, Christophe / Inman, Mark / Kuebler, Wolfgang M / Maes, Tania / Shi, Wei / Stampfli, Martin / Uhlig, Stefan / White, Eric / Witzenrath, Martin / Bellaye, Pierre-Simon / Crestani, Bruno / Eickelberg, Oliver / Fehrenbach, Heinz / Guenther, Andreas / Jenkins, Gisli / Joos, Guy / Magnan, Antoine / Maitre, Bernard / Maus, Ulrich A / Reinhold, Petra / Vernooy, Juanita H J / Richeldi, Luca / Kolb, Martin. ·Service de Pneumologie et Soins Intensifs Respiratoires, Centre Hospitalo-Universitaire de Bourgogne, Dijon, France. · Faculté de Médecine et Pharmacie, Université de Bourgogne-Franche Comté, Dijon, France. · INSERM U866, Dijon, France. · Dept of Histopathology, St Vincent's University Hospital, UCD School of Medicine, University College Dublin, Dublin, Ireland. · Laboratoire d'Innovation Thérapeutique, Université de Strasbourg, Strasbourg, France. · CNRS UMR 7200, Faculté de Pharmacie, Illkirch, France. · Labex MEDALIS, Université de Strasbourg, Strasbourg, France. · INSERM UMR_S 999, Le Plessis-Robinson, France. · Université Paris-Sud and Université Paris-Saclay, Le Kremlin-Bicêtre, France. · Dept of Medicine, Firestone Institute for Respiratory Health at St Joseph's Health Care MDCL 4011, McMaster University, Hamilton, ON, Canada. · Institute of Physiology, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Dept of Respiratory Medicine, Laboratory for Translational Research in Obstructive Pulmonary Diseases, Ghent University Hospital, Ghent, Belgium. · Developmental Biology and Regenerative Medicine Program, The Saban Research Institute of Children's Hospital Los Angeles, Los Angeles, CA, USA. · Dept of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. · Dept of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University. · Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany. · Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA. · Dept of Infectious Diseases and Respiratory Medicine And Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, Berlin, Germany. · Département de Médecine nucléaire, Plateforme d'imagerie préclinique, Centre George-François Leclerc (CGFL), Dijon, France. · Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, DHU FIRE, Service de Pneumologie A, Paris, France. · INSERM UMR 1152, Paris, France. · Université Paris Diderot, Paris, France. · Division of Pulmonary Sciences and Critical Care Medicine, Dept of Medicine, University of Colorado, Aurora, CO, USA. · Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany. · Member of the Leibniz Research Alliance Health Technologies. · Justus-Liebig-University Giessen, Universitary Hospital Giessen, Agaplesion Lung Clinic Waldhof-Elgershausen, German Center for Lung Research, Giessen, Germany. · Nottingham Biomedical Research Centre, Respiratory Research Unit, City Campus, University of Nottingham, Nottingham, UK. · Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium. · Institut du thorax, CHU de Nantes, Université de Nantes, Nantes, France. · Hôpital H Mondor, AP-HP, Centre Hospitalier Intercommunal de Créteil, Service de Pneumologie et de Pathologie Professionnelle, DHU A-TVB, Université Paris Est - Créteil, Créteil, France. · Hannover School of Medicine, Division of Experimental Pneumology, Hannover, Germany. · Institute of Molecular Pathogenesis at the 'Friedrich-Loeffler-Institut' (Federal Research Institute for Animal Health), Jena, Germany. · Dept of Respiratory Medicine, Maastricht University Medical Center+ (MUMC+), AZ Maastricht, The Netherlands. · UOC Pneumologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli", Rome, Italy. ·Eur Respir J · Pubmed #29773606.

ABSTRACT: Experimental models are critical for the understanding of lung health and disease and are indispensable for drug development. However, the pathogenetic and clinical relevance of the models is often unclear. Further, the use of animals in biomedical research is controversial from an ethical perspective.The objective of this task force was to issue a statement with research recommendations about lung disease models by facilitating in-depth discussions between respiratory scientists, and to provide an overview of the literature on the available models. Focus was put on their specific benefits and limitations. This will result in more efficient use of resources and greater reduction in the numbers of animals employed, thereby enhancing the ethical standards and translational capacity of experimental research.The task force statement addresses general issues of experimental research (ethics, species, sex, age,

15 Guideline 2018 AAHA Diabetes Management Guidelines for Dogs and Cats. 2018

Behrend, Ellen / Holford, Amy / Lathan, Patty / Rucinsky, Renee / Schulman, Rhonda. ·From the Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (E.B.) · Department of Small Animal Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee (A.H.) · Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi (P.L.) · Mid Atlantic Cat Hospital, Queenstown, Maryland (R.R.) · and Animal Specialty Group, Los Angeles, California (R.S.). ·J Am Anim Hosp Assoc · Pubmed #29314873.

ABSTRACT: Diabetes mellitus (DM) is a common disease encountered in canine and feline medicine. The 2018 AAHA Diabetes Management Guidelines for Dogs and Cats revise and update earlier guidelines published in 2010. The 2018 guidelines retain much of the information in the earlier guidelines that continues to be applicable in clinical practice, along with new information that represents current expert opinion on controlling DM. An essential aspect of successful DM management is to ensure that the owner of a diabetic dog or cat is capable of administering insulin, recognizing the clinical signs of inadequately managed DM, and monitoring blood glucose levels at home, although this is ideal but not mandatory; all topics that are reviewed in the guidelines. Insulin therapy is the mainstay of treatment for clinical DM. The guidelines provide recommendations for using each insulin formulation currently available for use in dogs and cats, the choice of which is generally based on efficacy and duration of effect in the respective species. Also discussed are non-insulin therapeutic medications and dietary management. These treatment modalities, along with insulin therapy, give the practitioner an assortment of options for decreasing the clinical signs of DM while avoiding hypoglycemia, the two conditions that represent the definition of a controlled diabetic. The guidelines review identifying and monitoring patients at risk for developing DM, which are important for avoiding unnecessary insulin therapy in patients with transient hyperglycemia or mildly elevated blood glucose.

16 Guideline European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers. 2017

Wess, G / Domenech, O / Dukes-McEwan, J / Häggström, J / Gordon, S. ·Clinic of Small Animal Medicine, LMU University, Veterinärstrasse 13, 80539 Munich, Germany. Electronic address: gwess@lmu.de. · Department of Cardiology, Istituto Veterinario di Novara, Granozzo con Monticello, Italy. · Small Animal Teaching Hospital, Department of Small Animal Clinical Science, Institute of Veterinary Science, University of Liverpool, Leahurst Campus, Chester High Road, Neston CH64 7TE, UK. · Department of Clinical Sciences, Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Box 7054, Uppsala, Sweden. · Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843-4474, United States. ·J Vet Cardiol · Pubmed #28965673.

ABSTRACT: BACKGROUND: Dilated cardiomyopathy (DCM) is the most common cardiac disease in large breed dogs and is inherited in Doberman Pinschers with a high prevalence (58%). OBJECTIVE: The European Society for Veterinary Cardiology convened a task force to formulate screening guidelines for DCM in Dobermans. RECOMMENDATIONS: Screening for occult DCM in Dobermans should start at three years of age and use both Holter monitoring and echocardiography. Yearly screening over the life of the dog is recommended, as a one-time screening is not sufficient to rule out future development of DCM. The preferred echocardiographic method is the measurement of the left ventricular volume by Simpson's method of discs (SMOD). Less than 50 single ventricular premature complexes (VPCs) in 24 h are considered to be normal in Dobermans, although detection of any number of VPCs is cause for concern. Greater than 300 VPCs in 24 h or two subsequent recordings within a year showing between 50 and 300 VPCs in 24 h is considered diagnostic of occult DCM in Dobermans regardless of the concurrent echocardiographic findings. The guidelines also provide recommendations concerning ancillary tests, that are not included in the standard screening protocol, but which may have some utility when recommended tests are not available or financially untenable on an annual basis. These tests include assay of cardiac biomarkers (Troponin I and N-Terminal pro-B-type Natriuretic Peptide) as well as a 5-min resting electrocardiogram (ECG). CONCLUSION: The current guidelines should help to establish an early diagnosis of DCM in Dobermans.

17 Guideline Treatment of bone and soft tissue tumors of the limbs with conformal radiotherapy and intensity-modulated radiotherapy (IMRT). 2017

Castilho, Marcus Simões / Ferrigno, Robson / Baraldi, Helena / Novaes, Paulo Eduardo Ribeiro Dos Santos / Anonymous3740918. ·Sociedade Brasileira de Radioterapia (SBR). ·Rev Assoc Med Bras (1992) · Pubmed #28876420.

ABSTRACT: -- No abstract --

18 Guideline 2017 AAHA Canine Vaccination Guidelines. 2017

Ford, Richard B / Larson, Laurie J / McClure, Kent D / Schultz, Ronald D / Welborn, Link V. ·North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina (R.B.F.). · Department of Pathobiological Sciences, University of Wisconsin-Madison School of Veterinary Medicine, Madison, Wisconsin (L.J.L.). · General Counsel, Animal Health Institute, Washington, DC (K.D.M.). · Department of Pathobiological Sciences, University of Wisconsin-Madison School of Veterinary Medicine, Madison, Wisconsin (R.D.S.). · Tampa Bay Animal Hospitals, Tampa, Florida (L.V.W.). ·J Am Anim Hosp Assoc · Pubmed #28846453.

ABSTRACT: -- No abstract --

19 Guideline Recommendations for approaches to meticillin-resistant staphylococcal infections of small animals: diagnosis, therapeutic considerations and preventative measures.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. 2017

Morris, Daniel O / Loeffler, Anette / Davis, Meghan F / Guardabassi, Luca / Weese, J Scott. ·Department of Clinical Studies - Philadelphia, School of Veterinary Medicine, University of Pennsylvania, 3900 Delancey St, Philadelphia, PA, 19104, USA. · Department of Clinical Sciences and Services, Royal Veterinary College, University of London, Hawkshead Lane, North Mymms, Hertfordshire, AL9 7TA, UK. · Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA. · Department of Biomedical Sciences, School of Veterinary Medicine, Ross University, Basseterre, St Kitts and Nevis, West Indies. · Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada, N1G 2W1. ·Vet Dermatol · Pubmed #28516494.

ABSTRACT: BACKGROUND: Multiple drug resistance (MDR) in staphylococci, including resistance to the semi-synthetic penicillinase-resistant penicillins such as meticillin, is a problem of global proportions that presents serious challenges to the successful treatment of staphylococcal infections of companion animals. OBJECTIVES: The objective of this document is to provide harmonized recommendations for the diagnosis, prevention and treatment of meticillin-resistant staphylococcal infections in dogs and cats. METHODS: The authors served as a Guideline Panel (GP) and reviewed the literature available prior to September 2016. The GP prepared a detailed literature review and made recommendations on selected topics. The World Association of Veterinary Dermatology (WAVD) provided guidance and oversight for this process. A draft of the document was presented at the 8th World Congress of Veterinary Dermatology (May 2016) and was then made available via the World Wide Web to the member organizations of the WAVD for a period of three months. Comments were solicited and posted to the GP electronically. Responses were incorporated by the GP into the final document. CONCLUSIONS: Adherence to guidelines for the diagnosis, laboratory reporting, judicious therapy (including restriction of use policies for certain antimicrobial drugs), personal hygiene, and environmental cleaning and disinfection may help to mitigate the progressive development and dissemination of MDR staphylococci.

20 Guideline Diagnosis and treatment of dermatophytosis in dogs and cats.: Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. 2017

Moriello, Karen A / Coyner, Kimberly / Paterson, Susan / Mignon, Bernard. ·Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI, 53706, USA. · Dermatology Clinic for Animals, 8300 Quinault Drive NE Suite A, Lacey, WA, 98516, USA. · Department of Veterinary Dermatology, Rutland House Referral Hospital, Abbotsfield Road, St Helens, WA9 4HU, UK. · Department of Infectious and Parasitic Diseases, Veterinary Mycology, FARAH (Fundamental and Applied Research for Animals & Health), Faculty of Veterinary Medicine, University of Liège, Quartier Vallée 2, Avenue de Cureghem 10, B43A, 4000, Liège, Belgium. ·Vet Dermatol · Pubmed #28516493.

ABSTRACT: BACKGROUND: Dermatophytosis is a superficial fungal skin disease of cats and dogs. The most common pathogens of small animals belong to the genera Microsporum and Trichophyton. It is an important skin disease because it is contagious, infectious and can be transmitted to people. OBJECTIVES: The objective of this document is to review the existing literature and provide consensus recommendations for veterinary clinicians and lay people on the diagnosis and treatment of dermatophytosis in cats and dogs. METHODS: The authors served as a Guideline Panel (GP) and reviewed the literature available prior to September 2016. The GP prepared a detailed literature review and made recommendations on selected topics. The World Association of Veterinary Dermatology (WAVD) provided guidance and oversight for this process. A draft of the document was presented at the 8th World Congress of Veterinary Dermatology (May 2016) and was then made available via the World Wide Web to the member organizations of the WAVD for a period of three months. Comments were solicited and posted to the GP electronically. Responses were incorporated by the GP into the final document. CONCLUSIONS: No one diagnostic test was identified as the gold standard. Successful treatment requires concurrent use of systemic oral antifungals and topical disinfection of the hair coat. Wood's lamp and direct examinations have good positive and negative predictability, systemic antifungal drugs have a wide margin of safety and physical cleaning is most important for decontamination of the exposed environments. Finally, serious complications of animal-human transmission are exceedingly rare.

21 Guideline Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. 2017

Hausenloy, Derek J / Garcia-Dorado, David / Bøtker, Hans Erik / Davidson, Sean M / Downey, James / Engel, Felix B / Jennings, Robert / Lecour, Sandrine / Leor, Jonathan / Madonna, Rosalinda / Ovize, Michel / Perrino, Cinzia / Prunier, Fabrice / Schulz, Rainer / Sluijter, Joost P G / Van Laake, Linda W / Vinten-Johansen, Jakob / Yellon, Derek M / Ytrehus, Kirsti / Heusch, Gerd / Ferdinandy, Péter. ·The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, 149 Tottenham Court Road London, W1T 7DN, UK; Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, 8 College Road, Singapore 169857; National Heart Research Institute Singapore, National Heart Centre Singapore, 5 Hospital Dr, Singapore 169609, Singapore; Yong Loo Lin School of Medicine, National University Singapore, Singapore; Barts Heart Centre, St Bartholomew's Hospital, London, UK. · Department of Cardiology, Vall d Hebron University Hospital and Research Institute. Universitat Autònoma, Passeig de la Vall d'Hebron, 119-129, 08035 Barcelona, Spain. · Department of Cardiology, Aarhus University Hospital Skejby, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark. · The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK. · Department of Physiology and Cell Biology, College of Medicine, University of South Alabama, 5851 USA Dr. N., MSB 3074, Mobile, AL 36688, USA. · Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nßrnberg, Schloßplatz 4, 91054 Erlangen, Germany. · Department of Cardiology, Duke University, Durham, NC 27708, USA. · Department of Medicine,  Hatter  Institute for Cardiovascular Research in Africa and South African Medical Research Council Inter-University Cape Heart Group, Faculty of Health Sciences, University of Cape Town, Chris Barnard Building, Anzio Road, Observatory, 7925, Cape Town, Western Cape, South Africa. · Tamman Cardiovascular Research Institute, Sheba Medical Center, Tel Hashomer, Israel; Neufeld Cardiac Research Institute, Tel-Aviv University, Sheba Medical Center, Tel Hashomer, 5265601, Israel; Sheba Center for Regenerative Medicine, Stem Cell, and Tissue Engineering, Tel Hashomer, 5265601, Israel. · Center of Aging Sciences and Translational Medicine - CESI-MeT, "G. d'Annunzio" University, Chieti, Italy; Institute of Cardiology, Department of Neurosciences, Imaging, and Clinical Sciences, "G. d'Annunzio University, Chieti, Italy; Texas Heart Institute and University of Texas Medical School in Houston, Department of Internal Medicine, 6770 Bertner Avenue, Houston, Texas 77030 USA. · Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, 28 Avenue du Doyen Jean Lépine, 69500 Bron, France; UMR 1060 (CarMeN), Université Claude Bernard Lyon, 43 Boulevard du 11 Novembre 1918, 69100 Villeurbanne, France. · Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University Corso Umberto I, 40, 80138 Napoli, Italy. · Department of Cardiology, University of Angers, University Hospital of Angers, 4 Rue Larrey, 49100 Angers, France. · Institute of Physiology, Justus-Liebig, University of Giessen, Ludwigstraße 23, 35390 Gießen, Germany. · Cardiology and UMC Utrecht Regenerative Medicine Center, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands. · Division Heart and Lungs, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, Netherlands. · Division of Cardiothoracic Surgery, Department of Surgery, Emory University, 201 Dowman Dr, Atlanta, GA 30322, USA. · The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, 149 Tottenham Court Road London, W1T 7DN, UK. · Cardiovascular Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Hansine Hansens veg 18, 9019 Tromsø, Norway. · Institute for Pathophysiology, West-German Heart and Vascular Center, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany. · Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Nagyvárad tér 4, 1089 Hungary; Pharmahungary Group, Graphisoft Park, 7 Záhony street, Budapest, H-1031, Hungary. ·Cardiovasc Res · Pubmed #28453734.

ABSTRACT: Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic-however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.

22 Guideline ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. 2017

Taylor, Samantha S / Sparkes, Andrew H / Briscoe, Katherine / Carter, Jenny / Sala, Salva Cervantes / Jepson, Rosanne E / Reynolds, Brice S / Scansen, Brian A. ·1 International Cat Care/ISFM, Tisbury, Wiltshire SP3 6LD, UK. · 2 Animal Referral Hospital, 250 Parramatta Road, Homebush, Sydney, NSW 2140, Australia. · 3 PO Box 128209, Remuera, Auckland 1541, New Zealand. · 4 Clínica Felina Barcelona, C/Marqués de Campo Sagrado 12, Barcelona, Spain. · 5 Clinical Sciences and Services, Royal Veterinary College, Hawkshead Lane, Hatfield, Hertfordshire, AL9 7TA, UK. · 6 Université de Toulouse, ENVT, Toulouse, France. · 7 Associate Professor, Department of Clinical Sciences, Colorado State University, Campus Delivery 1678, Fort Collins, CO 80523, USA. ·J Feline Med Surg · Pubmed #28245741.

ABSTRACT: Practical relevance: Feline hypertension is a common disease in older cats that is frequently diagnosed in association with other diseases such as chronic kidney disease and hyperthyroidism (so-called secondary hypertension), although some cases of apparent primary hypertension are also reported. The clinical consequences of hypertension can be severe, related to 'target organ damage' (eye, heart and vasculature, brain and kidneys), and early diagnosis followed by appropriate therapeutic management should help reduce the morbidity associated with this condition. Clinical challenges: Despite being a common disease, routine blood pressure (BP) monitoring is generally performed infrequently, probably leading to underdiagnosis of feline hypertension in clinical practice. There is a need to: (i) ensure BP is measured as accurately as possible with a reproducible technique; (ii) identify and monitor patients at risk of developing hypertension; (iii) establish appropriate criteria for therapeutic intervention; and (iv) establish appropriate therapeutic targets. Based on current data, amlodipine besylate is the treatment of choice to manage feline hypertension and is effective in the majority of cats, but the dose needed to successfully manage hypertension varies between individuals. Some cats require long-term adjuvant therapy and, occasionally, additional therapy is necessary for emergency management of hypertensive crises. Evidence base: These Guidelines from the International Society of Feline Medicine (ISFM) are based on a comprehensive review of the currently available literature, and are aimed at providing practical recommendations to address the challenges of feline hypertension for veterinarians. There are many areas where more data is required which, in the future, will serve to confirm or modify some of the recommendations in these Guidelines.

23 Guideline Antimicrobial use Guidelines for Treatment of Respiratory Tract Disease in Dogs and Cats: Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases. 2017

Lappin, M R / Blondeau, J / Boothe, D / Breitschwerdt, E B / Guardabassi, L / Lloyd, D H / Papich, M G / Rankin, S C / Sykes, J E / Turnidge, J / Weese, J S. ·Colorado State University, Fort Collins, CO, Denmark. · University of Saskatoon, Saskatoon, SK, Denmark. · Auburn University, Auburn, AL, Denmark. · North Carolina State University, Raleigh, NC, Denmark. · University of Copenhagen, Copenhagen, Denmark. · Royal Veterinary College, London, UK. · University of Pennsylvania, Philadelphia, PA, Australia. · University of California, Davis, CA, Australia. · The Women's and Children Hospital, Adelaide, SA,, Australia. · Ontario Veterinary College, Guelph, ON, Australia. ·J Vet Intern Med · Pubmed #28185306.

ABSTRACT: Respiratory tract disease can be associated with primary or secondary bacterial infections in dogs and cats and is a common reason for use and potential misuse, improper use, and overuse of antimicrobials. There is a lack of comprehensive treatment guidelines such as those that are available for human medicine. Accordingly, the International Society for Companion Animal Infectious Diseases convened a Working Group of clinical microbiologists, pharmacologists, and internists to share experiences, examine scientific data, review clinical trials, and develop these guidelines to assist veterinarians in making antimicrobial treatment choices for use in the management of bacterial respiratory diseases in dogs and cats.

24 Guideline Guidelines for the Direct Detection of Anaplasma spp. in Diagnosis and Epidemiological Studies. 2017

Silaghi, Cornelia / Santos, Ana Sofia / Gomes, Jacinto / Christova, Iva / Matei, Ioana Adriana / Walder, Gernot / Domingos, Ana / Bell-Sakyi, Lesley / Sprong, Hein / von Loewenich, Friederike D / Oteo, José A / de la Fuente, José / Dumler, J Stephen. ·1 National Center for Vector Entomology, Vetsuisse Faculty, University of Zurich , Zurich, Switzerland . · 2 Center for Vector and Infectious Diseases Research, National Institute of Health Doutor Ricardo Jorge , Águas de Moura, Portugal . · 3 Animal Health and Production Unit, National Institute for Agrarian and Veterinary Research , Oeiras, Portugal . · 4 Department of Microbiology, National Center of Infectious and Parasitic Diseases , Sofia, Bulgaria . · 5 Department of Parasitology and Parasitic Diseases, Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca , Cluj-Napoca, Romania . · 6 Department of Hygiene, Medical Microbiology and Social Medicine, Innsbruck Medical University , Innsbruck, Austria . · 7 Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa , Lisboa, Portugal . · 8 The Pirbright Institute , Ash Road, Pirbright, Woking, Surrey, United Kingdom . · 9 Center for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM) , Bilthoven, the Netherlands . · 10 Department of Medical Microbiology and Hygiene, University of Mainz , Medical Center, Mainz, Germany . · 11 Infectious Diseases Department, Center of Rickettsioses and Arthropod-Borne Diseases , Hospital San Pedro- CIBIR, Logroño, Spain . · 12 SaBio. Instituto de Investigación de Recursos Cinegéticos, IREC-CSIC-UCLM-JCCM, Ciudad Real, Spain . · 13 Department of Veterinary Pathobiology, Center for Veterinary Health Sciences, Oklahoma State University , Stillwater, Oklahoma. · 14 Departments of Pathology and Microbiology and Immunology, University of Maryland , School of Medicine, Baltimore, Maryland. · 15 Department of Pathology, Uniformed Services University for the Health Sciences "America's Medical School," Bethesda, Maryland. ·Vector Borne Zoonotic Dis · Pubmed #28055579.

ABSTRACT: The genus Anaplasma (Rickettsiales: Anaplasmataceae) comprises obligate intracellular Gram-negative bacteria that are mainly transmitted by ticks, and currently includes six species: Anaplasma bovis, Anaplasma centrale, Anaplasma marginale, Anaplasma phagocytophilum, Anaplasma platys, and Anaplasma ovis. These have long been known as etiological agents of veterinary diseases that affect domestic and wild animals worldwide. A zoonotic role has been recognized for A. phagocytophilum, but other species can also be pathogenic for humans. Anaplasma infections are usually challenging to diagnose, clinically presenting with nonspecific symptoms that vary greatly depending on the agent involved, the affected host, and other factors such as immune status and coinfections. The substantial economic impact associated with livestock infection and the growing number of human cases along with the risk of transfusion-transmitted infections, determines the need for accurate laboratory tests. Because hosts are usually seronegative in the initial phase of infection and serological cross-reactions with several Anaplasma species are observed after seroconversion, direct tests are the best approach for both case definition and epidemiological studies. Blood samples are routinely used for Anaplasma spp. screening, but in persistently infected animals with intermittent or low-level bacteremia, other tissues might be useful. These guidelines have been developed as a direct outcome of the COST action TD1303 EURNEGVEC ("European Network of Neglected Vectors and Vector-Borne Diseases"). They review the direct laboratory tests (microscopy, nucleic acid-based detection and in vitro isolation) currently used for Anaplasma detection in ticks and vertebrates and their application.

25 Guideline Guidelines for the Detection of Babesia and Theileria Parasites. 2017

Lempereur, Laetitia / Beck, Relja / Fonseca, Isabel / Marques, Cátia / Duarte, Ana / Santos, Marcos / Zúquete, Sara / Gomes, Jacinto / Walder, Gernot / Domingos, Ana / Antunes, Sandra / Baneth, Gad / Silaghi, Cornelia / Holman, Patricia / Zintl, Annetta. ·1 Laboratory of Parasitology and Parasitic Diseases, Faculty of Veterinary Medicine, University of Liège , Liège, Belgium . · 2 Laboratory for Parasitology, Croatian Veterinary Institute , Zagreb, Croatia . · 3 Faculty of Veterinary Medicine, Centre for Interdisciplinary Research in Animal Health, University of Lisbon , Lisbon, Portugal . · 4 National Institute for Agrarian and Veterinary Research , Oeiras, Portugal . · 5 Department of Hygiene and Medical Microbiology, Innsbruck Medical University , Innsbruck, Austria . · 6 Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical (IHMT) , Lisbon, Portugal . · 7 Koret School of Veterinary Medicine, Hebrew University , Rehovot, Israel . · 8 National Centre for Vector Entomology, Institute of Parasitology, University of Zurich , Zurich, Switzerland . · 9 Veterinary Medicine and Biomedical Sciences, Texas A&M University , College Station, Texas. · 10 UCD Veterinary Sciences Centre, University College Dublin , Belfield, Dublin, Ireland . ·Vector Borne Zoonotic Dis · Pubmed #28055573.

ABSTRACT: The genera Babesia and Theileria (phylum Apicomplexa, order Piroplasmida) are mainly transmitted by Ixodid ticks in which the sexual part of their life cycle followed by sporogony takes place. They include protozoan parasites that infect erythrocytes of a variety of vertebrate hosts, including domestic and wild animals, with some Babesia spp. also infecting humans. Babesia sporozoites transmitted in the tick's saliva during the bloodmeal directly infect erythrocytes, where they asexually multiply to produce pear-shaped merozoites in the process of merogony; whereas a pre-erythrocytic schizogonic life stage in leukocytes is found in Theileria and precedes merogony in the erythrocytes. The wide spectrum of Babesia and Theileria species and their dissimilar characteristics with relation to disease severity, transmission, epidemiology, and drug susceptibility stress the importance of accurate detection of babesiosis and theileriosis and their causative agents. These guidelines review the main methods currently used for the detection of Babesia and Theileria spp. for diagnostic purposes as well as epidemiological studies involving their vertebrate hosts and arthropod vectors. Serological methods were not included once they did not indicate current infection but rather exposure.

Next